Biotech Lock-Up Expiration Hell Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (674)	4/11/2002 9:35:53 AM
From: tuck	Read Replies (1) of 1005

>>CHAPEL HILL, N.C., April 11 /PRNewswire-FirstCall/ -- POZEN Inc. (Nasdaq: POZN - news) a pharmaceutical development company with a portfolio of product candidates for the treatment of migraine, announced that it successfully completed its second study comparing MT 100 to the leading migraine product in the U.S., Imitrex® 50 mg. 1,027 migraine patients completed this double-blind, placebo-controlled trial, which was conducted at 41 centers around the United States. The trial results indicate that a single tablet dose of MT 100 provided comparable efficacy to Imitrex® 50 mg. and was superior to placebo for both two hour pain relief and sustained pain relief, confirming the results of a previously completed Phase III trial. The FDA usually requires at least two studies with similar results to support promotional claims. MT 100 is being developed as an oral, first-line treatment for migraine. POZEN has completed all planned Phase III pivotal trials for MT 100, which has consistently demonstrated its effectiveness in treating migraine pain with less risk of cardiovascular side effects compared to leading products on the market today.<< snip Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next